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Abstract
Interactions between the inflammatory chemokine CCL20 and its receptor CCR6 have been associated with colorectal
cancer growth and metastasis, however, a causal role for CCL20 signaling through CCR6 in promoting intestinal
carcinogenesis has not been demonstrated in vivo. In this study, we aimed to determine the role of CCL20-CCR6 interactions
in spontaneous intestinal tumorigenesis. CCR6-deficient mice were crossed with mice heterozygous for a mutation in the
adenomatous polyposis coli (APC) gene (APC
MIN/+ mice) to generate APC
MIN/+ mice with CCR6 knocked out (CCR6KO-
APC
MIN/+ mice). CCR6KO-APC
MIN/+ mice had diminished spontaneous intestinal tumorigenesis. CCR6KO-APC
MIN/+ also had
normal sized spleens as compared to the enlarged spleens found in APC
MIN/+ mice. Decreased macrophage infiltration into
intestinal adenomas and non-tumor epithelium was observed in CCR6KO-APC
MIN/+ as compared to APC
MIN/+ mice. CCL20
signaling through CCR6 caused increased production of CCL20 by colorectal cancer cell lines. Furthermore, CCL20 had a
direct mitogenic effect on colorectal cancer cells. Thus, interactions between CCL20 and CCR6 promote intestinal
carcinogenesis. Our results suggest that the intestinal tumorigenesis driven by CCL20-CCR6 interactions may be driven by
macrophage recruitment into the intestine as well as proliferation of neoplastic epithelial cells. This interaction could be
targeted for the treatment or prevention of malignancy.
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Introduction
Cytokines likely play a key role in the crosstalk between
neoplastic cells and the inflammatory milieu. Chemokines are a
family of small (8–10 kDa) cytokines with shared structural
characteristics that are most known for directing the migration
and homing of immune cells. Chemokines also play a crucial role
in shaping host immunity through their involvement in processes
such as the formation of lymphoid organs, wound healing,
angiogenesis, and inflammation [1,2]. Recently, it has been
suggested that chemokines can play a role in cancer development
and metastasis [1,3].
Chemokines exert their effects when recognized by G-protein
coupled cell surface chemokine receptors. Chemokine receptors
often recognize several chemokines, and chemokines often bind
to multiple receptors [1–3]. The C-C chemokine CCL20, also
known as macrophage infiltrating factor protein-3 a (MIP-3 a)
and liver activation regulated chemokine (LARC), however, is
the only known ligand for the receptor CCR6, which in turn is
the only known receptor for CCL20 [4]. CCR6-CCL20
interactions have been shown to be involved in several
autoimmune and inflammatory processes such as rheumatoid
arthritis, [5] multiple sclerosis [6,7], psoriasis [8], and inflam-
matory bowel disease [9]. Of note, inflammation is particularly
important in sporadic intestinal tumorigenesis [10–15].
The expression of CCL20 and CCR6 has been documented in
several tumor types including colorectal cancer [16–22]. Further-
more, it has been shown that CCL20-CCR6 interactions promote
increased proliferation [23,24] and invasion [23] in colorectal
cancer cell lines. The aim of this study was to assess the role of
CCL20-CCR6 interactions in a mouse model of intestinal
tumorigenesis.
Materials and Methods
Ethics statement
Written patient consent was obtained for collection of speci-
mens. The experimental protocol was approved by the VA Boston
Healthcare System Institutional Review Board (IRB). Animal
experiments in this study were carried out in strict accordance with
the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
experimental protocol was approved by the VA Boston Healthcare
System Institutional Animal Care and Use Committee (IACUC)
(Protocol #291-W-111009).
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Tissue samples were acquired immediately after resection from
patients having surgery for colorectal cancer at the VA Boston
Healthcare System.
Animals
APC
MIN/+ mice (that express one allele of a mutant adenoma-
tous polyposis coli (APC) gene with a premature stop codon)
[25,26], CCR6 knockout (CCR6KO) mice (B6.129P2-Ccr6
tm1Dgen/
J), and wild-type (WT) C57/Bl6 mice were purchased from The
Jackson Laboratory (Bar Harbor, ME). APC
MIN/+ and CCR6KO
mice were intercrossed to generate CCR6KO-APC
MIN/+ and
CCR6HET-APC
MIN/+ (CCR6
+/2-APC
MIN/+) mice. The geno-
type was confirmed by performing PCR on DNA from tail snips
using primers and conditions provided by the Jackson Laboratory.
The mice were housed and maintained in the specific pathogen-
free (SPF) animal research facility of VA Boston Healthcare
System.
Cell lines
The murine colon cancer cell line MC38 [27] was kindly
provided by Michael T. Lotze of the University of Pittsburgh.
The human colon cancer cell lines HT29 and Hct116 were
purchased from American Type Culture Collection (ATCC;
Manassas, VA). Cell lines were grown in RPMI 1640 (Life
Technologies, Grand Island, NY) with 10% fetal bovine serum
(FBS) (Life Technologies).
Quantification of polyps
After euthanasia, intestines were dissected from the mice. The
intestines were flushed with cold phosphate buffered saline (PBS)
to remove fecal material, and then cut into three equal length
segments: duodenum, jejunum and ileum. Each segment was then
cut open longitudinally and examined under a dissection
microscope at 10X magnification. Polyps were counted and
measured at their greatest diameter. The polyp mass was defined
as the sum of the greatest diameters for each polyp.
Immunohistochemistry
Tissue rolls of each segment of mouse intestine were fixed in
10% formalin and then embedded in paraffin. Five micron tissue
sections were cut and mounted on glass slides. Hematoxylin and
eosin stains were performed for reference. Immunohistochemical
staining was performed as described in the Dako EnVision kit
(Dako North America, Inc, Carpinteria, CA) instruction manual
and as detailed in the Methods S1. The primary antibodies
utilized were anti-mouse B220 (clone-RA3-6B2, BD Biosciences,
San Jose, CA), anti-mouse CD3 (Clone-SP7, Abcam, Cambridge,
MA), anti-mouse F4/80 (clone-A3-1, AbD Serotec US, Raleigh,
NC), anti-mouse FoxP3, (clone- FJK-16, eBioscience, San Diego,
CA), anti-human CD163 (clone-10D6, Vector Laboratories
Burlingame, CA), anti-human CCR6 (clone- 53103, R&D
Systems, Minneapolis, MN), anti-human CCL20 (Polyclonal Goat
IgG, R&D Systems). Cells were quantified by manual counting of
10 40X fields by a single blinded observer.
ELISA
Snap frozen sections of mouse intestine or of human tissue
were stored at 280uC until use. Homogenates were prepared
either using the Tissue Lyser II (Qiagen, Valencia, CA) in a
volume of 200 ml of PBS or using an Eppendorf micropestle in
1 ml Eppendorf tubes (Eppendorf, Hauppauge, NY) with 200 ml
of PBS. The homogenized samples were then centrifuged at
13,000 rpm for 10 minutes to remove debris, and the superna-
tant was collected for analysis. Protein concentration was
measured using the Quick Start Bradford protein assay (Bio-
Rad Life Sciences, Hercules, CA). CCL20 levels in human or
mouse tissue homogenates or in human or mouse cell culture
supernatants were measured using ELISA kits for human or
mouse CCL20 (R&D Systems) following the manufacturer’s
protocol.
Western blot analysis
[LOOSESTCells were lysed using NP40 cell lysis buffer (Life
Technologies). Cell lysates were separated by SDS-PAGE using a
precast 4–15% gel (Bio-Rad, Hercules, CA) and blotted on
nitrocellulose membranes (Bio-Rad, Hercules, CA) that were then
washed with Tris-buffered saline (TBS) and blocked with fat-free
milk in the same buffer for 1 hour at room temperature. The
membranes were subject to incubation with a primary rat
monoclonal antibody directed against mouse CCR6 (clone
CKR-6 (13Q7), dilution 1:200) or a mouse anti-b-actin antibody
(clone ACTBD11B7, dilution 1:1000) (both from Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) overnight at 4uC. The
following day, the membranes were washed and incubated with
goat anti-rat IgG-HRP conjugated secondary antibody (for anti-
CCR6 primary antibody) and secondary goat anti-mouse IgG-
HRP (for anti-b-actin primary antibody) (both at 1:5000 dilution,
Santa Cruz Biotechnology, Inc.). Finally, the membranes were
developed by using the Amersham ECL Plus kit (GE Healthcare,
Piscataway, NJ) as per the manufacturer’s protocol.
Immunofluorescence
2610
5 MC38 cells were allowed to adhere in 2 chambered Lab-
Tek 4.2 cm
2 slides (Thermo Scientific, Rochester, NY) overnight.
The next day, the cells were washed with PBS and blocked with
donkey serum (1:100 dilution in PBS, Millipore, Billerica, MA) for
2 hours. Next, the cells were washed with PBS and then incubated
with rat anti-mouse CCR6 monoclonal antibody (clone CKR-6
(13Q7), dilution 1:100, Santa Cruz Biotechnology, Inc.) and
polyclonal rabbit anti-cytokeratin antibody (dilution 1:500, Dako)
for 1.5 hours. The cells were washed again with PBS and then
incubated with the secondary antibodies Cy5 goat anti-rat IgG
and Alexa Fluor 546 goat anti-rabbit IgG antibody (both from Life
Technologies) at 5 mg/ml in PBS for 1 hour. The cells were then
washed and stained with SYBR Green (dilution 1:50,000, Life
Technologies) for 10 minutes. Finally, the slides were washed with
PBS and air dried. The sections were sealed with a coverslip using
Vectashield mounting media (Vector Laboratories) and examined
using a confocal microscope.
MTT assay
The Vybrant MTT Cell Proliferation MTT Assay Kit (Life
Technologies) was used according to the manufacturer’s instruc-
tions. In brief, 5610
3 MC38, HT29 or Hct116 cells were cultured
in 100 ml of RPMI media without serum and without phenol red
(Life Technologies) for 24 or 48 hours in 96 well cell culture plates.
After incubation, the media was replaced with 100 ml of fresh
media, and then 10 ml of 12 mM MTT solution (component A)
was added to each culture well. The cells were then incubated for
4 hours at 37uC. Next, 100 ml of the SDS-HCl solution
(component B) was added to each well, and the cells were
incubated for another 12 hours. After incubation, the samples
were mixed well, and absorbance was quantified at 570 nm using
a spectrophotometer.
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Total RNA was extracted either from tumor tissue of
colorectal cancer patients or from cultured MC38, HT29 or
Hct116 cells using the RNAeasy Plus Universal Kit (Qiagen,
Valencia, CA). Before extracting total RNA, cell lysates were
prepared from 100 mg of tumor tissue samples by mixing with
900 ml of QIAzol Lysis Reagent (Qiagen) in an Eppendorf tube
followed by homogenization using the Tissue Lyser II (Qiagen).
For making cell lysates from MC38, HT29 and Hct116 cells,
2610
5 cells were mixed with 1 ml of the QIAzol Lysis Reagent.
For cDNA synthesis, 1 mg of total RNA samples were reverse-
transcribed using the SuperScript III First-Strand Synthesis
System (Life Technologies) where oligo-dT was used as first
synthesis primer. Semi-quantitative RT-PCR for CCR6 was
performed on cDNA prepared from patient tumor tissue. The
primers [28] and conditions are detailed in the Methods S1.
Statistical analysis
Differences between means were assessed using the two-tailed
Student’s unpaired t-test. Differences in values for paired samples
were assessed using the Wilcoxon signed-rank test. A p value ,
0.05 was considered significant.
Results
CCL20 and CCR6 are overexpressed in human colon
cancer
To assess for an association of CCL20 and its receptor CCR6
with colorectal cancer, we evaluated the expression of CCL20 and
CCR6 in human tumors. Levels of CCL20 were measured in
matched samples of colorectal cancer and adjacent uninvolved
colon by ELISA. While the levels of CCL20 in both non-diseased
colonic tissue and colon cancer varied substantially between
patients, a significant increase of CCL20 was observed in the
tumors compared to the matched controls (Figure 1A). We next
sought to determine the cells in the tumor microenvironment that
express CCL20. Human colon cancers immunohistochemically
stained for CCL20 showed high to moderate expression of CCL20
in the malignant epithelial cells in all 11 patient samples (data not
shown), however, expression of CCL20 by infiltrating stromal cells
was also noted (Figure 1B). Expression of CCR6, the receptor for
CCL20 in human colorectal tumors and adjacent uninvolved
colon was measured by semi quantitative RT-PCR (Figure 1C).
Relative expression of Ccr6 normalized to the house-keeping gene
b-actin was compared between normal and tumor tissue. Ccr6 was
found to be expressed at a higher level in tumor tissue as compared
to adjacent uninvolved normal tissue. Similar to CCL20, as
determined by immunohistochemistry, CCR6 was expressed at
high to moderate levels by malignant epithelial cells and to a lesser
degree by infiltrating stromal cells (Figure 1D).
CCR6KO-APC
MIN/+ mice develop fewer intestinal
adenomas than APC
MIN/+ mice with intact CCR6
To address the role of CCL20-CCR6 interactions in intestinal
tumorigenesis in vivo, we bred APC
MIN/+ mice to CCR6-deficient
(CCR6KO or CCR6
2/2) mice to create APC
MIN/+ mice lacking
either one or both alleles of CCR6 (CCR6HET-APC
MIN/+ or
CCR6
+/2-APC
MIN/+ mice and CCR6KO-APC
MIN/+ or
CCR6
2/2-APC
MIN/+ mice respectively). APC
MIN/+ mice have a
single defective allele of APC and sporadically develop intestinal
adenomas and early carcinomas [25,26]. Phenotypically,
CCR6KO-APC
MIN/+ mice were seen to develop fewer intestinal
adenomas (Figure 2A–B) and to have normal sized spleens
compared to APC
MIN/+ mice (Figure 2C). APC
MIN/+ mice have
large spleens associated with vigorous splenic hematopoiesis,
possibly related to intestinal bleeding from the polyps [29].
The number of polyps and the size of each polyp in the small
intestine were recorded for mice of 15 weeks and 22 weeks of
age. At both time points, CCR6KO-APC
MIN/+ mice had an
approximately 2-fold decrease in the total number of intestinal
tumors compared to that found in APC
MIN/+ mice. The
number of polyps in the CCR6HET-APC
MIN/+ mice was
intermediate (Figure 3A left panels). We then analyzed polyp
number for each segment of the small intestine (Figure 3A right
panels). APC
MIN/+ mice develop the majority of the intestinal
polyps in the ileum with the remaining polyps mostly arising in
the jejunum. We found reduction of polyp number in all
segments of the intestine for CCRKO-APC
MIN/+ mice as
compared to APC
MIN/+ mice at both time points, although the
reduction in the duodenum was not statistically significant at
15 weeks of age. We further quantified the burden of intestinal
adenomas by calculating total polyp mass (Figure S1). Total
polyp mass in the entire small intestine was approximately 3-
fold lower in CCR6KO-APC
MIN/+ mice as compared to
APC
MIN/+ mice at both the 15 and 22 week time points
(Figure S1A left panels). Similarly, the polyp mass was
decreased in all the segments of the small intestine in the
CCR6KO-APC
MIN/+ mice (Figure S1A right panels).
In our colony, APC
MIN/+ mice almost uniformly meet end-
points for euthanasia by 25 weeks of age. In contrast, CCR6KO-
APC
MIN/+ mice were observed to be grossly healthy without any
overt signs of distress at 30 weeks (Figure S2). Thus, we quantified
adenoma burden in CCR6KO-APC
MIN/+ mice at 30 weeks of
age. At this time point, the polyp number was approximately half
(Figure 3B) and the total polyp mass was approximately 2/3
(Figure S1B) of that seen in APC
MIN/+ mice at 15 weeks of age.
Decreased macrophage infiltration into adenomas and
non-tumor epithelium in CCR6KO-APC
MIN/+ mice as
compared to APC
MIN/+ mice without alterations in T cell,
Treg, or B cell infiltration
Interactions between CCL20 and CCR6 are known to be
particularly important for the migration of Th17 cells and Tregs
into the intestine [30]. For these reasons, we suspected that
alterations in the homing of immune cells might contribute to
the decreased tumor formation in CCR6KO-APC
MIN/+ mice.
To explore this possibility, we evaluated the degree of
infiltration of different immune cells (T cells, Tregs, B cells,
and macrophages) in situ by immunohistochemically staining
tissue sections of mouse ileum for CD3, FoxP3, B220, and F4/
80 respectively and quantifying the number of stained cells in
both the adenomas and non-tumor epithelium. We did not find
significant differences in the infiltration of CD3
+ cells, FoxP3
+
cells or B220
+ cells in either adenomas or non-tumor epithelium
between CCR6KO-APC
MIN/+ and APC
MIN/+ mice as shown in
Figure 4A–C (representative photomicrographs are shown in
Figure S3). Counter-intuitively, in the absence of CCR6, there
was a trend toward increased T cell infiltration into both
adenomas and non-tumor epithelium. There was minimal
infiltration of CD3
+ cells, FoxP3
+ cells, or B220
+ cells in
adenomas in either group when compared to adjacent non-
tumor epithelium. Of note, we detected similar numbers of
CD3
+ cells and FoxP3
+ cells in the adenomas in both groups
suggesting that most of the T cells in the adenomas were Tregs.
In contrast, only 16% and 10% of CD3
+ T cells in the
uninvolved epithelium were FoxP3
+ cells in APC
MIN/+ and
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MIN/+ mice respectively. We did note a signif-
icant reduction in the number of F4/80
+ cells in both tumors
and uninvolved epithelium (Figure 4D) of the CCR6KO-
APC
MIN/+ mice. A significant number of macrophages were
also found infiltrating human colorectal cancers (mean
=36.163 cells/0.01 mm
2, range =17.2–50.2) in the 11 tumors
assessed as determined by immunohistochemical staining for
CD163 (Figure S4) [31].
CCL20 signaling through CCR6 promotes further
production of CCL20 and induces proliferation of
colorectal cells
We next assayed the levels of CCL20 in the ileum of
APC
MIN/+ and CCR6KO-APC
MIN/+ mice at 15 weeks of age
by subjecting homogenized tissue samples to ELISA. CCR6KO-
APC
MIN/+ mice were observed to have a significantly lower
level of ileal CCL20 than that found in APC
MIN/+ mice
(Figure 5A). This finding implied that lack of CCR6 results in
decreased production of CCL20. In order to determine whether
signaling through CCR6 causes production of CCL20, we used
ELISA to assay levels of CCL20 in the supernatant of MC38
murine colorectal cancer cells and splenocytes isolated either
from wild-type or CCR6KO mice upon stimulation with
CCL20. First, we checked for expression of CCR6 on the
MC38 cell line. MC38 cell lysate was subjected to Western blot
analysis with lysates of splenocytes from wild-type and
CCR6KO mice used as positive and negative controls
respectively. Our data demonstrate that CCR6 is expressed in
this cell line (Figure 5B left panel). We next used immunoflu-
orescence staining of cytospin samples of MC38 to confirm
MC38 expression and determine its cellular location. Strong cell
surface expression of CCR6 was observed (Figure 5B right
panel). We then assayed for production of CCL20 by MC38 in
response to CCL20 signaling. We pulsed MC38 cells with
CCL20 for one hour, and then washed the cells and replaced
the media. CCL20 concentration was assessed from 30 to
90 minutes after the stimulation. Stimulation of MC38 colorec-
tal cancer cells with CCL20 resulted in a surge of CCL20
production at 30 minutes with a 2-fold increase by 60 minutes.
CCL20 production appeared to plateau between 60 and
90 minutes (Figure 5C left panel). Next, we assayed CCL20
production in response to CCL20 in splenocytes from wild-type
and CCR6KO mice to determine the role of CCR6 in CCL20-
mediated CCL20 production. Wild-type splenocytes showed a 2-
fold increase in CCL20 production compared to CCR6KO
splenocytes 30 minutes after stimulation. Again, CCL20 pro-
duction by wild-type splenocytes increased another 2-fold by
60 minutes, and production plateaued by 90 minutes (Figure 5C
Figure 1. Expression of CCL20 and CCR6 in colon cancer. (A) CCL20 concentration was assayed by ELISA in 12 matched samples of colon
cancer and adjacent normal colon tissue after homogenizing approximately 100 mg of tissue into 100 ml PBS. The Wilcoxon signed-rank test was
used to assess significance. (B) Representative photomicrograph of a section of paraffin-embedded human colon cancer tumor tissue
immunohistochemically stained for CCL20. The regions in the squares are shown magnified. (C) Relative expression of human Ccr6 is compared
in 10 matched samples of colon cancer and adjacent uninvolved colon tissue as measured by semiquantitative RT-PCR. (D) Representative
photomicrograph of a section of paraffin-embedded human colon cancer tumor tissue immunohistochemically stained for CCR6. The regions in the
squares are shown magnified.
doi:10.1371/journal.pone.0097566.g001
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demonstrated by the human colorectal cancer cell lines HT29
and Hct116 when exposed to CCL20 (Figure 5D). To exclude
the possibility that the CCL20 expression we measured by
ELISA in cells exposed to CCL20 was related to CCL20
dissociating from its receptor CCR6, we analyzed for Ccl20
expression by quantitative reverse-transcription PCR. While the
kinetics of Ccl20 expression after exposure to CCL20 varied
between MC38, HT29, and Hct116, an approximately 2–6 fold
increase in Ccl20 was seen in these cell lines after stimulation
with CCL20 (Figure S5A–C). We further demonstrated that the
measured CCL20 expression was partially dependent on protein
synthesis occurring after the CCL20 exposure by using
cyclohexamide (a pan-protein synthesis inhibitor). MC38 cells
were exposed to cyclohexamide for 4 hours prior to adminis-
tration of CCL20, and CCL20 levels were then measured by
ELISA. The presence of cyclohexamide significantly reduced the
measured CCL20 at 60 and 90 minutes after withdrawal of
CCL20 (Figure S5D). These experiments demonstrate that the
Figure 2. CCR6KO-APC
MIN/+ mice develop fewer intestinal
adenomas and have larger spleens. (A) Representative ileal
segments obtained from APC
MIN/+ (CCR6WT- APC
MIN/+) and CCR6KO-
APC
MIN/+ mice at 15 weeks of age magnified under a dissection
microscope at 10X magnification. (B) Representative photomicrographs
of hematoxylin and eosin stained slides of ileum collected from APC
MIN/
+ and CCR6KO- APC
MIN/+ mice at 15 weeks of age. Tumors are marked
by red dashed lines and normal epithelium is marked by green dashed
lines (left panel). The regions in the squares are shown magnified (right
panel). (C) Representative spleens from APC
MIN/+ and CCR6KO-APC
MIN/+
mice are shown in the left panel. Comparison of the mean spleen size
for these two groups of mice (n=8–13 per group) is shown in the right
panel.
doi:10.1371/journal.pone.0097566.g002
Figure 3. CCR6KO-APC
MIN/+ mice develop fewer intestinal
adenomas. (A) Polyp number is shown for the entire small intestine
(left panels) and in the duodenum, jejunum and ileum individually
(right panels) as compared between APC
MIN/+, CR6HET- APC
MIN/+, and
CCR6KO- APC
MIN/+ mice at 15 and 22 weeks of age (n=6–9 mice per
group at each time point). (B) Polyp number in the entire small intestine
is shown for CCR6KO- APC
MIN/+ and APC
MIN/+ mice at 15, 22 and
30 weeks of age. APC
MIN/+ mice could not be kept to 30 weeks of age
as they uniformly reached endpoints for euthanasia.
doi:10.1371/journal.pone.0097566.g003
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auto-feedback loop regulation of CCL20 production.
Having shown an auto-feedback loop in CCL20 production,
we sought to confirm that CCL20 could induce proliferation of
colorectal cancer cells. We subjected the MC38 cell line to the
MTT assay after exposure to CCL20 or IL-6, which has
previously been shown to increase proliferation of MC38 [32].
CCL20 induced a gradual increase in proliferation of MC38
cells in both a temporal- and concentration-dependent manner
(Figure 6A). CCL20 similarly promoted proliferation in the
human colorectal cancer cell lines HT29 and Hct116
(Figure 6B). The proliferative activity of CCL20 on the
colorectal cancer cell lines was further confirmed using the
3H-thymidine incorporation assay (Figure S6).
Discussion
The secretion of various soluble signaling molecules by resident
stromal cells, infiltrating immune cells, and neoplastic tumor cells
themselves is an important factor in tumor initiation and
progression. Chemokines may play an important role in the
crosstalk between immune cells and neoplastic tumor cells [1,3]
and as such may mediate the tumor promoting effects of
inflammatory immune responses. In this study, we examined the
role of the chemokine CCL20, which is the sole known ligand for
the receptor CCR6, itself the sole known receptor for CCL20 [4],
in intestinal tumorigenesis.
Recent evidence suggests a possible role for CCR6-CCL20
interactions in colorectal cancer. Expression of CCL20 and
CCR6 has been observed in several malignancies including
colorectal cancer [16–22]. A possible role of CCL20 in the liver
mediating metastasis of CCR6-expressing colorectal cancer cells
has been explored [16,20,21]. In fact, high serum levels of
CCL20 have been shown to correlate with poor prognosis of
the disease in human patients suggesting a possible causal role
for CCL20-CCR6 interactions in promoting tumors [33].
Furthermore, direct effects of CCL20 in increasing proliferation
[23,24] and invasion [23] in colorectal cancer cell lines have
been demonstrated in vitro. In addition to acting directly on
neoplastic tumor cells, it is also conceivable that CCL20-CCR6
interactions promote cancer through their role in inflammation.
CCL20 and CCR6 have been shown to be important mediators
of various inflammatory [5–9]. Inflammation is now recognized
as playing an important role in sporadic intestinal tumorigenesis
[10–15], and this association has been repeatedly demonstrated
in the APC
MIN/+ mouse model.[10,12,13,15].
The primary aim of this study was to evaluate the role of the
disruption of CCL20-CCR6 interactions in a model of sporadic
intestinal tumorigenesis. While blockade of CCL20-CCR6 inter-
actions has been shown to decrease colorectal tumor growth in a
xenograft model [28] and administration of exogenous CCL20 has
been shown to promote growth of syngeneic transplanted
colorectal tumors [34], to our knowledge the effect of blockade
of CCL20-CCR6 interactions on intestinal carcinogenesis in vivo in
the setting of an intact host immune system has not been reported.
Our data clearly show that CCR6 is an important factor in the
sporadic development of intestinal adenomas as its absence results
in a marked decrease in adenomas by 2 measures at 2 time points.
The decrease was noted in each segment of the small intestine in
the APC
MIN/+ mouse model. We further noted that APC
MIN/+
mice without functional CCR6 appeared to live longer and to be
healthy at a later time point due to the decreased adenoma
development. CCR6KO-APC
MIN/+ mice were observed to have
smaller spleens than APC
MIN/+ mice. Adenoma-bearing APC
MIN/
+ mice have characteristically larger spleens as compared to non-
adenoma bearing wild-type mice. This has been attributed to
extramedullary hematopoiesis, as these animals are typically
anemic due to the intestinal adenomas [29]. It is also possible
that the enlarged spleens are partially related to an altered
immune system in APC
MIN/+ mice [10] but in either case, spleen
size in APC
MIN/+ mice typically correlates with the burden of
intestinal adenomas.
We also made interesting initial observations on the potential
mechanism of CCR6 in adenoma development. We noted
decreased infiltration of F4/80
+ macrophages in adenomas and
non-adenoma intestinal epithelium of CCR6KO-APC
MIN/+ mice
Figure 4. Macrophage infiltration into adenomas and non-
tumor epithelium is decreased in CCR6KO-APC
MIN/+ mice.
Sections of paraffin-embedded immunohistochemically stained ileum
from CCR6KO-APC
MIN/+ and APC
MIN/+ mice at 22 weeks of age were
examined (n=6–7 animals per group). Infiltrating (A) CD3
+, (B) Foxp3
+,
(C) B220
+, and (D top panels) F4/80
+ cells were counted. Representative
photomicrographs magnification showing macrophage infiltration in
adenomas and normal epithelium in the ileum of APC
MIN/+ and
CCR6KO-APC
MIN/+ mice are shown (D bottom panels).
doi:10.1371/journal.pone.0097566.g004
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infiltration. Indeed CCL20 (also known as macrophage inflam-
matory protein-3a) has been shown to play an important role in
the maturation of intestinal macrophages [35] and in the
migration of macrophage-lineage cells such as Langerhans cells
[36] and dendritic cells [37]. A tumor promoting role of tumor
associated macrophages (TAMs) has been demonstrated for many
cancer types in many models [38]. Interestingly, a role for
macrophages in promoting colorectal cancer has been noted by a
recent paper where the effect appeared to be at least partially due
to the loss of macrophage-generated CCL20 [34]. The role for
macrophages in intestinal tumorigenesis was also supported by
another recent paper demonstrating that knockout of monocyte
chemoattractant protein 1 (MCP-1) in APC
MIN/+ mice is
associated with decreased macrophages in intestinal adenomas
and non-adenoma intestinal epithelium as well as decreased
adenoma formation [39]. Another recent study demonstrated that
myeloid cells, particularly Gr1
+ but also F4/80
+ and CD11b
+ cells,
respond to intestinal microbiota by secreting IL-23, which is
particularly important in the development of adenomas in the
colon of mice with an APC mutation [11].
Figure 5. CCL20-CCR6 interactions induce the production of CCL20. (A) CCL20 concentrations in the ileum of APC
MIN/+ and CCR6KO-APC
MIN/
+ mice at 15 weeks of age as measured by ELISA are shown. (Representative data from 1 of 2 experiments is shown.) (B) CCR6 expression is
demonstrated in the murine colorectal cancer cell line MC38 both by Western blot analysis comparing cell lysates of MC38 cells, WT spleen, and
CCR6KO spleen (left panel); and by immunofluorescence staining of cytospin specimens of MC38 cells (right panel). (C) CCL20-induced production of
CCL20 was measured by exposing MC38 cells (left panel) as well as WT and CCR6KO splenocytes (right panel) to CCL20 at 50 ng/ml for 1 hour and
analyzing culture supernatants 30, 60 and 90 minutes after withdrawal of CCL20. (Representative data from 1 of 3 experiments is shown.) (D) CCL20
was measured after exposing the human colon cancer cell lines HT29 (left panel) and Hct116 (right panel) to 50 ng/ml CCL20 for 1 hour and
analyzing culture supernatants 30, 60 and 90 minutes after withdrawal of CCL20. (Representative data from 1 of 2 experiments is shown.).
doi:10.1371/journal.pone.0097566.g005
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adenomas or non-adenoma intestinal epithelium of CCR6KO-
APC
MIN/+ mice as compared to APC
MIN/+ mice, and in fact there
was a trend toward an increase in T cell infiltration. Similarly, we
did not notice differences in the infiltration of B cells or Tregs
(regulatory T cells). These results are in line with reports from
other groups showing an apparent increase in T cell infiltration
and no change in B cell infiltration in the intestinal epithelium of
CCR6KO mice [40,41]. Of note, another group found that Treg
migration into colorectal cancer was dependent on CCL20-CCR6
signaling for tumors induced by the carcinogen N-methyl-N-
nitrosourea (MNU) or the bacterium H. pylori as well as in a
syngeneic transplantable tumor model [34]. Perhaps, the influence
of CCL20-CCR6 interactions on Treg migration into colorectal
cancer is dependent on the model. It is possible, for instance, that
Treg trafficking to colorectal cancer is controlled differently than
to adenomas. It is also possible that the difference could be
explained by the fact that our study employed a sporadic
carcinogenesis model as opposed to models where tumors are
induced under inflammatory conditions or transplanted hetero-
topically into mice. Interestingly, in our study it appears that the
vast majority of the CD3
+ T cells in adenomas of APC
MIN/+ mice
are Tregs as determined by expression of FoxP3.
Our data also showed that there is less CCL20 in the small
intestine of CCR6KO-APC
MIN/+ mice as compared to APC
MIN/+
mice. This observation prompted us to investigate if CCL20
signaling through CCR6 promotes further secretion of CCL20.
We demonstrated that this indeed was the case using a murine
colorectal cancer cell line and 2 human colorectal cell lines as well
as murine splenocytes. We further confirmed that CCL20 induces
proliferation in the murine and human colorectal cancer cell lines
as has been shown by other groups for human colorectal cancer
cell lines [23,24].
Further studies, however, will be required to determine the
precise mechanism by which CCL20-CCR6 interactions promote
intestinal tumorigenesis. The relative role of direct effects on
neoplastic epithelial cells as compared to effects on stromal cells
such as macrophages remains to be elucidated.
In summary, loss of CCR6 disrupts the formation of intestinal
adenomas in a murine model of intestinal carcinogenesis. Loss of
CCR6 is also associated with decreased CCL20 levels in the
intestine of this mouse model as CCL20-CCR6 interactions
promote further secretion of CCL20. Disruption of CCL20-CCR6
Figure 6. CCL20 induces proliferation in colon cancer cells. (A) Proliferation of MC38 cells after 24 and 48 hours of exposure to CCL20 at
concentrations of 10 and 50 ng/ml, IL-6, or serum-free media as measured by the MTT assay is shown. (Representative data from 1 of 2 experiments is
shown.) (B) Proliferation of HT29 (left) and Hct116 (right) cells after 24 and 48 hours of exposure to CCL20 at concentrations of 10 and 50 ng/ml.
(Representative data from 1 of 2 experiments is shown.).
doi:10.1371/journal.pone.0097566.g006
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decreased proliferation of neoplastic epithelial cells. The relative
contributions of these 2 effects to decreased tumorigenesis as well
as the mechanism by which these effects are mediated remain to
be elucidated.
Our results suggest an important role of CCL20-CCR6 in
intestinal neoplasia. The role of CCL20-CCR6 interactions in
tumor development, however, is likely not restricted to this model.
Associations between CCL20-CCR6 interactions and many
cancer types have been suggested. As such, blockade of this
interaction warrants further investigation as a potential target for
the treatment and prevention of malignancy.
Supporting Information
Figure S1 CCR6KO-APC
MIN/+ mice develop reduced
polyp mass. (A) Polyp mass is shown for the entire small
intestine (left panels) and the duodenum, jejunum and ileum
individually (right panels) as compared between APC
MIN/+,
CR6HET- APC
MIN/+, and CCR6KO- APC
MIN/+ mice at 15
and 22 weeks of age (n=6–9 mice per group at each time point).
(B) Polyp mass in the entire small intestine is shown for CCR6KO-
APC
MIN/+ and APC
MIN/+ mice at 15, 22 and 30 weeks of age.
APC
MIN/+ mice could not be kept to 30 weeks of age as they
uniformly reached endpoints for euthanasia.
(TIF)
Figure S2 CCR6KO-APC
MIN/+ mice grossly appear
healthy up to 30 weeks of age. Representative pictures of
APC
MIN/+ and CCR6KO-APC
MIN/+ of 22 weeks and 30 weeks
of age.
(TIF)
Figure S3 T cell, Treg, or B cell infiltration is
unchanged between CCR6KO-APC
MIN/+ mice and APC-
MIN/+ mice. Representative photomicrographs of sections of
paraffin-embedded ileum from APC
MIN/+ (top panels) and
CCR6KO-APC
MIN/+ (bottom panels) mice at 22 of weeks age
immunohistochemically stained for (A) CD3, (B) Foxp3, and (C)
B220 cells are shown in adenoma (left panel) and normal
epithelium (right panel).
(TIF)
Figure S4 Infiltration of macrophages in human colo-
rectal cancer. A representative photomicrograph of a paraffin-
embedded section of colorectal cancer immunohistochemically
stained with an antibody specific for CD163 is shown.
(TIF)
Figure S5 Exposure to CCL20 induces expression of
Ccl20 and CCL20 protein synthesis. Ccl20 expression as
measured by quantitative RT-PCR after exposure to 50 ng/ml
CCL20 for 1 hour and isolation of RNA at 30, 60 and 90 minutes
following withdrawal of CCL20 is shown for MC38 (A), HT29 (B)
and Hct116 (C) cell lines. Relative expression was normalized to
gapdh and calculated using the 2
2DDCt method. (Representative
data from 1 of 2 experiments is shown.) (D) CCL20-induced
production of CCL20 in MC38 cells either with or without
cyclohexamide treatment (5 mg/ml for 4 hours prior to CCL20
exposure) was measured after exposing cells to CCL20 at 50 ng/
ml for 1 hour and analyzing culture supernatants 30, 60 and
90 minutes after withdrawal of CCL20. * p,.05.
(TIF)
Figure S6 CCL20 induces proliferation in colon cancer
cells. Proliferation of MC38, HT29 and Hct116 cells measured
by
3H-thymidine incorporation assay after 48 hours of exposure to
CCL20 at 50 ng/ml. Data are shown as percentage increase in
proliferation compared to cells cultured in the absence of CCL20.
*p ,.05.
(TIF)
Methods S1 Supplementary Materials and Methods.
(DOC)
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